News from the BioRegion STERN

Here you'll find all press releases and news from companies and institutes in the STERN BioRegion.

08/13/2019 | Insilico Biotechnology AG

Predictive Digital Twins control bioprocesses for the production of monoclonal antibodies

Insilico Biotechnology AG and the Laboratory of Systems Theory and Automatic Control at the Institute for Automation Engineering (IFAT) of the Otto von Guericke University Magdeburg started a joint project on model predictive control (MPC) for the production of monoclonal antibodies in mammalian cell culture processes using Insilico's Digital Twins...
08/12/2019 | Curetis GmbH

Curetis Retains H.C. Wainwright & Co. as Strategic Advisor

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has retained the U.S. based investment bank, H.C. Wainwright & Co., LLC, as strategic advisor in an  effort to assess all available strategic and tactical options going forward to po...
08/08/2019 | Curetis GmbH

Curetis Group Company Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH has opened a specialized service laboratory offeringnext-generation molecular antimicrobial resistance (AMR)testing services with an initial focus ...
07/19/2019 | immatics biotechnologies GmbH

Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced today a comprehensive data set having completed the first cohort of the ACTolog®...
07/17/2019 | Atriva Therapeutics GmbH

Atriva Therapeutics Receives EU Award for Biomarker Validation

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME. A total of four award winners will receive a grant of approximately 100,000 Euros each, in the form of labo...
07/12/2019

Towards personalized medicine: 5 West-Holland companies get support from Codex4SME’s

The Interreg project Codex4SMEs (Companion diagnostics expedited for small and medium-sized businesses) project plans to improve healthcare by enhanced adoption of Personalized Medicine in North-West Europe. The objective is to establish a network, which supports SMEs along the value chain of Companion diagnostics (Cdx) development.
07/08/2019 | immatics biotechnologies GmbH

Immatics Appoints Harpreet Singh as Chief Executive Officer

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).
07/04/2019 | Curetis GmbH

Curetis Group Company Ares Genetics is Granted Key European Patent on Genetic Resistance Testing

Patent broadly covers genetic biomarkers and biomarker combinations indicating antibiotic resistance, First of eleven similar patents filed covering various pathogen/drug combinations, Strengthens unique position of ARESdb, Ares Genetics’ knowledgebase of antimicrobial resistance genetics  
07/01/2019 | CureVac AG

European Commission Appoints CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, to the European Innovation Council Advisory Board

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, congratulates CureVac co-founder and Chairman of the Supervisory Board, Ingmar Hoerr, following his appointment as a Member of the European Innovation Council (EIC) Advisory Board.
05/23/2019 | Curetis GmbH

Curetis Reports Positive Results from Clinical Validation Study for U.S. FDA 510(k) Submission of Unyvero LRT for BAL Samples

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced key data from its successfully completed Unyvero LRT clinical performance evaluation study for BAL samples.
05/21/2019 | Curetis GmbH

Curetis to Receive Additional EUR 6.5 Million Financing from EIB and Yorkville

Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that Curetis will receive another EUR 6.5 million in gross proceeds under two financing facilities.  
05/17/2019 | Curetis GmbH

Curetis Announces Financial Results for the First Three Months of 2019

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first threemonths ended March31, 2019,and provided a business update for 2019.
05/15/2019 | Atriva Therapeutics GmbH

Atriva Therapeutics Starts Clinical Development of novel Host-Targeting Antiviral ATR-002 Against Influenza

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the first dosing of its lead drug candidate ATR-002 in a Phase I clinical trial (EudraCT 2019-000784-25). The dosing marks the start of the clinical development of this novel host-targeted approach to treating infl...
04/09/2019 | immatics biotechnologies GmbH

Immatics Initiates Third Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers

Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA203, its third T-cell receptor (TCR)-transduced adoptive cell therapy program. IMA203 is an investigational immunotherapy which uses Immatics’ proprietary ACTengine® approach and is based on genet...
04/04/2019

Retina Implant AG discontinues business activities

Unfortunately, the history of our company is coming to an end. The shareholders of Retina Implant AG resolved to dissolve the company at an extraordinary general meeting held on 19 March 2019.
04/02/2019 | Curetis GmbH

Curetis Introduces Unyvero AMR Atlas to Support Adoption of Rapid DNATesting for Antibiotic Resistance

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it will introduce its newly developed Unyvero AMR Atlas at the upcoming 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), which will take place in Amsterdam, th...
03/26/2019 | Curetis GmbH

Curetis and Menarini Diagnostics Enter into Strategic Pan-European Exclusive Partnership for the Distribution of Curetis’ Unyvero

Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that it has entered into an exclusive long-term strategic distribution partnership with A. Menarini Diagnostics (“AMD”).
03/20/2019 | Mireca Medicines GmbH

Mireca’s key patent application receives “Notice of Allowance” from USPTO

Tübingen, Germany, February 20th, 2019 – Mireca Medicines GmbH, an ophthalmology start-up company developing treatments for inherited retinal degeneration, receives the validating “Notice of Allowance” from the USPTO for its proprietary formulation and medical use patent application “Targeted liposomal delivery of cGMP analogues” (PCT/EP2016/055659...
03/19/2019

Idris Oncology one of first companies to receive free human tissue through Codex4SME’s

The Leiden based biotechnology firm Idris Oncology is one of the three SME’s in Europe to receive human tissue through the Codex4SME’s consortium, in order to help them progress their diagnostic product towards clinical application. Interreg project Codex4SME's supports entrepreneurs in Life Sciences & Health sector in obtaining human tissue fr...